503 related articles for article (PubMed ID: 21793014)
1. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
León R; Garcia AG; Marco-Contelles J
Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic agents against Alzheimer's disease from natural sources.
Park SY
Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
[TBL] [Abstract][Full Text] [Related]
4. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
Mazumder MK; Choudhury S
Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
[TBL] [Abstract][Full Text] [Related]
5. Drugs targeting Alzheimer's disease: some things old and some things new.
Michaelis ML
J Pharmacol Exp Ther; 2003 Mar; 304(3):897-904. PubMed ID: 12604663
[TBL] [Abstract][Full Text] [Related]
6. Secretases as therapeutic targets for Alzheimer's disease.
Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
[TBL] [Abstract][Full Text] [Related]
7. Management of oxidative stress and other pathologies in Alzheimer's disease.
Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
[TBL] [Abstract][Full Text] [Related]
8. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
9. Sarsasapogenin: A steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer's disease.
Kashyap P; Muthusamy K; Niranjan M; Trikha S; Kumar S
Steroids; 2020 Jan; 153():108529. PubMed ID: 31672628
[TBL] [Abstract][Full Text] [Related]
10. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
11. Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration.
Amadoro G; Corsetti V; Atlante A; Florenzano F; Capsoni S; Bussani R; Mercanti D; Calissano P
Neurobiol Aging; 2012 Apr; 33(4):833.e1-25. PubMed ID: 21958963
[TBL] [Abstract][Full Text] [Related]
12. γ-Secretase as a target for Alzheimer's disease.
Wolfe MS
Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
[TBL] [Abstract][Full Text] [Related]
13. Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment.
Gazova Z; Soukup O; Sepsova V; Siposova K; Drtinova L; Jost P; Spilovska K; Korabecny J; Nepovimova E; Fedunova D; Horak M; Kaniakova M; Wang ZJ; Hamouda AK; Kuca K
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):607-619. PubMed ID: 27865910
[TBL] [Abstract][Full Text] [Related]
14. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ε-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model.
Zara S; Rapino M; Sozio P; Di Stefano A; Nasuti C; Cataldi A
Brain Res; 2011 Sep; 1412():79-87. PubMed ID: 21820649
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's disease pathogenesis and therapeutic interventions.
Parihar MS; Hemnani T
J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
18. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
Ling S; Zhou J; Rudd JA; Hu Z; Fang M
Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
[TBL] [Abstract][Full Text] [Related]
19. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.
Phiel CJ; Wilson CA; Lee VM; Klein PS
Nature; 2003 May; 423(6938):435-9. PubMed ID: 12761548
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease: emerging trends in small molecule therapies.
Mohamed T; Rao PP
Curr Med Chem; 2011; 18(28):4299-320. PubMed ID: 21861820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
